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Abstract
Type I galactosemia is a genetic disorder that is caused by the impairment of galactose-1-
phosphate uridylyltransferase (GALT; EC 2.7.7.12). Although a large number of mutations have
been detected through genetic screening of the human GALT (hGALT) locus, for many it is not
known how they cause their effects. The majority of these mutations are missense, with predicted
substitutions scattered throughout the enzyme structure and thus causing impairment by other
means rather than direct alterations to the active site. To clarify the fundamental, molecular basis
of hGALT impairment we studied five disease-associated variants p.D28Y, p.L74P, p.F171S,
p.F194L and p.R333G using both a yeast model and purified, recombinant proteins. In a yeast
expression system there was a correlation between lysate activity and the ability to rescue growth
in the presence of galactose, except for p.R333G. Kinetic analysis of the purified proteins
quantified each variant’s level of enzymatic impairment and demonstrated that this was largely
due to altered substrate binding. Increased surface hydrophobicity, altered thermal stability and
changes in proteolytic sensitivity were also detected. Our results demonstrate that hGALT requires
a level of flexibility to function optimally and that altered folding is the underlying reason of
impairment in all the variants tested here. This indicates that misfolding is a common, molecular
basis of hGALT deficiency and suggests the potential of pharmacological chaperones and
proteostasis regulators as novel therapeutic approaches for type I galactosemia.
Keywords
GALT; yeast model; disease associated mutation; stability; substrate binding; protein misfolding
1. Introduction
Type I galactosemia (OMIM #230400) is a genetic disorder that is caused by impairment of
galactose-1-phosphate uridylyltransferase (GALT; EC 2.7.7.12) [1]. Two other forms of
galactosemia are also recognized: galactokinase deficiency (type II; OMIM #230200) and
UDP-galactose 4′-epimerase deficiency (type III; OMIM #230350) [2;3]. GALT is involved
in the metabolism of galactose and it catalyses the reversible conversion of UDP-glucose
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and galactose-1-phosphate to UDP-galactose and glucose-1-phosphate via an uridylated
enzyme intermediate [4;5]. Deficiency of human GALT (hGALT) is detected through
newborn screening in many developed countries minimizing the acute pathology that can
otherwise include jaundice, cataracts, vomiting, diarrhea, hepatomegaly, sepsis and neonatal
death [6]. Galactose restriction in the diet can immediately mitigate or prevent these acute
manifestations, but does not appear to prevent longer-term complications that include
ovarian failure and disabilities in learning and speech, among other problems [7]. The
underlying mechanism of these long-term pathologies is not fully known, and the role of
accumulated galactose-1-phosphate in the process remains controversial [8]. In addition,
understanding phenotype-genotype correlations is difficult as compound heterozygosity
plays a role in disease [9]. This is because the hGALT protein functions as a dimer (Figure
1) [10-12]. However, recently the level of predicted residual GALT activity associated with
genotype of a cohort of school-age children with type I galactosemia was demonstrated to
influence the level of scholastic achievement of those students in mathematics [13].
To date, 264 variants have been reported from genetic screening of the hGALT gene. Of
these, 159 are missense mutations and for the majority it is not known how they cause their
effects [14;15]. The most commonly detected severe mutant, Q188R, and selected others
have been studied using a yeast model [16-21] which has provided useful information about
the severity of each mutation in vivo. However, detailed functional and structural analyses
have been lacking, as only a small number of variants have been studied in any detail in
vitro [12;22-27].
It is interesting that although a number of mutations are located in the active site of hGALT
and therefore are predicted to affect catalysis directly, the majority are located elsewhere
throughout the enzyme’s structure [28;29]. Computational analysis using a homology model
of hGALT has suggested that these mutations alter hydrogen bond networks and
hydrophobic interactions. Decreased monomer stability was predicted for over half of the
studied variants, which suggests that they may cause protein misfolding [28;29]. More
recently it has been shown that disease-associated mutants affect the expression and
solubility of hGALT in an E. coli expression system. Molecular dynamics simulations
predicted that these mutations affect the overall flexibility of the enzyme thus altering
substrate affinity [30]. Similarly, previous studies have shown that some mutants can cause
temperature sensitivity and decreased levels of expression in yeast [20;21]. Effects on dimer
formation have also been detected which further supports the hypothesis that alterations in
overall structure are involved [12;25].
Since misfolding has not been experimentally verified for the majority of hGALT mutants
[15] five representative variants, p.D28Y, p.L74P, p.F171S, p.F194L and p.R333G were
studied here with the aim of establishing whether, or not, this is a common feature of
variants associated with type I galactosemia. These variants have been previously found to
be associated with type I galactosemia (Table S1) and all five variants are classified as
pathogenic in the hGALT mutant database [14]. Only p.F171S and p.L74P are located at the
active site (Figure 1) and both have been shown to severely impair enzyme activity (Table
S1) [19;20;31]. The remaining three variants are located away from the active site and all
five have been included in a recent molecular modelling study of variant GALT enzymes
[29]. Thus the studied set represents a diverse group of mutants, which have previously been
clinically characterised (Table S1) and subject to, at least, some theoretical analysis. Each of
the five mutants was studied in terms of their effects in vivo using an established yeast
model and in vitro with the recombinant, purified variant proteins from a bacterial
expression system to determine their stability, substrate binding, ability to dimerise and
enzyme kinetics in the forward and reverse directions.
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2. Materials & Methods
2.1 Expression of hGALT alleles in yeast
Each hGALT allele was recreated by site-directed mutagenesis of the centromeric yeast
vector pMM22.hGALT as described previously [20;21] and confirmed by dideoxy
sequencing of the entire GALT open reading frame. Creation and analysis of the F171S
substitution has been described previously in the context of other studies [19;20]. The
primers used to generate these alleles are listed in Table S2.
Each plasmid was transformed into each of two haploid strains of Saccharomyces
cerevisiae: JFy3747 [21], which is deficient in GAL7, the gene encoding endogenous yeast
GALT [32], and JFy5555, which is deficient in GAL7 and also deficient in GAL1 and
GAL10, which encode the endogenous yeast GALK and GALE enzymes, respectively [32].
JFy3747 was used as the host for all growth curve experiments, and JFy5555 was used as
the host for all biochemical studies performed using yeast lysates. All yeast strains were
grown on medium lacking tryptophan to maintain selection for the MM22-based plasmids.
2.2 Enzyme activities from soluble yeast lysates
GALT activity assays were performed using soluble protein lysates from JFy5555
expressing each of the desired GALT alleles, essentially as described previously [21] except
that progress of the reaction was quantified by monitoring the appearance of UDP-galactose
(in nmol UDP-gal/μg protein/min). Because the host yeast were deficient in GALK and
GALE as well as endogenous GALT there was essentially no background conversion of
UDP-glc to UDP-gal by GALE in the absence of GALT activity. The average ± SD (n=3) of
GALT enzyme activity for yeast expressing each allele was normalized to the activity level
observed in yeast expressing wild-type hGALT from the same plasmid backbone.
2.3 Yeast growth studies
Colonies of JFy3747 yeast expressing the desired alleles of hGALT were cultured and
assessed for growth in the wells of 96 well plates using SGE-trp medium with and without
0.01% galactose, as described previously [21]. OD600 readings from any wells that showed
evidence of air bubbles or clumping were excluded from analysis. The average ± SD of
OD600 readings from 3 separate wells representing yeast expressing each GALT allele and
galactose condition were plotted.
2.4 Expression and purification of recombinant proteins
The gene encoding hGALT was amplified by PCR from the IMAGE clone [33] number
3922902 and was cloned into the NdeI and EcoRI sites of pET43a using primers, which
incorporated sequence encoding a hexahistidine tag at the 5′ end. The insertion of the gene
into the recombinant expression vector was verified by sequencing and this plasmid was
then transformed into E. coli Rosetta(DE3) (Merck, Nottingham, UK). Single colonies
resulting from this transformation were picked and grown in 5 ml of LB (supplemented with
100 μg.ml−1 ampicillin, 34 μg.ml−1 chloramphenicol, 50 μM ZnCl2), shaking at 30°C
overnight. This culture was then diluted into 1 L of LB (supplemented with 100 μg.ml−1
ampicillin and 34 μg.ml−1 chloramphenicol, 50 μM ZnCl2) and grown, shaking at 30 °C
until A600nm was between 0.6 and 1.0 (typically 6 h). At this point the culture was induced
with 1 mM IPTG at 15 °C and grown for a further 20 h. Cells were harvested by
centrifugation at 4,200μg for 20 min and cell pellets were resuspended in buffer R (50 mM
HEPES, 5 mM imidazole, pH 7.5, 150 mM NaCl, 10 % (v/v) glycerol, 5 mM DTT). These
suspensions were frozen at −80 °C until required.
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The cell suspensions were thawed and the cells broken by sonication on ice (three 30 s
pulses of 100 W with 30 s gaps in between for cooling). The extract was centrifuged at
20,000μg for 20 min to remove insoluble material and the supernatant applied to a 1 ml
nickel agarose (Sigma, Poole, UK) column. Once this solution had passed through, the
column was washed with 20 ml buffer W (as buffer R, expect with 500 mM NaCl and 20
mM imidazole) and the protein eluted with a 2 ml wash of buffer E (buffer W supplemented
with 250 mM imidazole). The eluate was further purified by size exclusion chromatography
on a Sephacryl S-300 (Pharmacia) column (55 ml) at 4 °C with a mobile phase that
consisted of 50 mM HEPES, pH 7.5, 150 mM NaCl, 10 % (v/v) glycerol, 5 mM DTT. A
flow rate of 1 ml.min−1 was used and 1 ml fractions were collected. Control proteins of
known molecular mass were used to construct a standard curve and, thus, determine the
oligomeric state of hGALT. Protein containing fractions, (judged by absorbance at 280 nm)
corresponding to the molecular mass of hGALT dimers (87 kDa), were pooled together.
These pooled fractions were then concentrated using Amicon Ultra-4 (Millipore) centrifugal
filtration devices (cut-off of 3 kDa) at 4 °C to a final volume of ≈ 600 μl. The protein
solution was then divided into 30 μl aliquots and stored frozen at −80 °C.
The Quick Change protocol [34] was used to change the appropriate codons in the
expression vector. Successful mutagenesis was verified by sequencing (MWG-Biotech,
Ebersburg, Germany). These mutated plasmids were used to express p.D28Y, p.L74P,
p.F171S, p.F194L and p.R333G-hGALT using the same protocol as used with the wild-type
protein.
Recombinant human UDP-glucose dehydrogenase was expressed and purified as described
[35]. The expression and purification of all proteins was monitored by 10 % SDS-PAGE.
All protein concentrations were estimated using the Bradford assay [36] with bovine serum
albumin as standard.
2.5 Spectroscopic measurements
Intrinsic fluorescence of each hGALT variant was measured using 5.5 μM protein in 10 mM
HEPES, pH 8.8 in a total volume of 180 μl. The binding of 1-anilinonaphthalene-8-
sulphonic acid (ANS-1) was used to determine the degree of surface hydrophobicity with
each variant at 5 μM in 10 mM HEPES, pH 8.8 with 100 μM ANS-1 in a total volume was
200 μl. Samples with ANS-1 were incubated at room temperature in the dark for 30 min
before measurement. Fluorescence spectra were measured (in triplicate) at room temperature
using a Spectra Max Gemini X plate-reader fluorimeter (Molecular Devices. CA, USA) with
excitation at 280 nm, emission 300-500 nm, and a slit width of 10 nm for intrinsic
fluorescence. Excitation at 370 nm, emission 420-580 nm, and a slit width of 5 nm was
carried out for ANS-1 binding. Emission spectra were averaged for each variant and
corrected for the emission of buffer only or ANS-1 in buffer only, as appropriate.
2.6 Measurement of the steady state kinetic parameters for galactose-1-phosphate
uridylyltransferase
Enzymatic activities of the hGALT variants in the forward reaction were determined using a
spectrophotometric coupled assay based on that described previously [19] which couples the
production of glucose 1-phosphate to its isomerization to glucose 6-phosphate and
subsequent NADP+-dependent oxidation of this compound. The standard reaction was
performed at 37 °C and contained 10 mM HEPES, pH 8.8, 5 mM DTT, 5 mM glucose 1,6-
bisphosphate, 5 mM MgCl2, 0.8 mM NADP+, 0.03 mg glucose-6-phosphate dehydrogenase,
and 0.4 mg of phosphoglucomutase. Assays were performed in triplicate in a 96 well plate
format each with a total volume of 150 μl. Kinetic constants were determined for UDP-Glc
by varying its concentration from 0.01 to 1.0 mM while the concentration of Gal-1P was
McCorvie et al. Page 4













held at a constant 1.0 mM. Conversely the kinetic constants for Gal-1P were determined by
varying its concentration from 0.01 to 2.0 mM while UDP-Glc was held constant at 0.5 mM.
The amount of NADPH produced (detected by absorption at 340 nm) is equivalent to the
amount of Glc-1P formed.
Enzymatic activities of the hGALT variants in the reverse reaction were also determined
using a spectrophotometric coupled assay based on that described previously [37] which
couples the production of UDP-glucose to the NAD+-dependent oxidation of this compound.
The standard reaction was performed at 37 °C and contained 10 mM HEPES, pH 8.8, 5 mM
DTT, 5 mM MgCl2, 10 mM NAD+, 1.2 μM human UDP-glucose dehydrogenase. Assays
were performed in triplicate in a 96 well plate format each with a total volume of 150 μl.
Kinetic constants were determined for UDP-gal by varying its concentration from 0.01 to
1.0 mM while the concentration of Glc-1P was held at a constant 1.0 mM. Conversely the
kinetic constants of Glc-1P were determined by varying its concentration from 0.01 to 2.0
mM while UDP-gal was held constant at 0.5 mM. The amount NADH produced, measured
at 340 nm, is equivalent to twice the amount of UDP-Glc formed [38].
All reactions were monitored at 340 nm for 40 min at 37 °C using a Multiskan Spectrum
spectrophotometer (Thermo Scientific). Controls lacking either one or both substrates were
routinely included, for both forward and reverse kinetic assays, and always gave the
expected negative results.
The initial rate of product formation was plotted against substrate concentration and
analyzed using non-linear curve fitting of GraphPad Prism (GraphPad Software, CA, USA).
The data was fitted to either Michaelis-Menten (1), Michaelis-Menten with substrate
inhibition (2) or sigmoidal kinetics (3).
(1)
where  is the apparent maximum, limiting rate and  is the apparent Michaelis
constant.
(2)
where  is the apparent dissociation constant.
(3)
where h is the Hill coefficient and  is the concentration of substrate to give a rate equal
to half of . [S] is the concentration of the varied substrate for all equations. The
goodness of fit to these equations was compared using the F test and results are reported for
the best fit to the data
2.7 Chemical cross-linking
Before the addition of a chemical cross-linker, hGALT variants (5 μM in 10 mM HEPES,
pH 8.8) were incubated at 37 °C for 5 min with and without ligands (1 mM). BS3 (Sigma) or
glutaraldehyde (Sigma) was then added to final concentrations of 100 μM and 0.25 % (v/v)
respectively. Cross-linking was allowed to proceed for 30 min and was then halted by the
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addition of an equal volume of SDS loading buffer (125 mM tris-HCl, pH 6.8, 4% (w/v)
SDS, 20% (v/v) glycerol, 1% (w/v) dithiothreitol, 0.002% (w/v) bromophenol blue).
Samples were denatured at 95 °C for 5 min before analysis by 10 % SDS-PAGE.
2.8 Limited proteolysis
hGALT variants (5 μM in 10 mM HEPES, pH 8.8) were incubated at 37 °C for 5 min with
and without ligands (1 mM). Thermolysin, trypsin or chymotrypsin (Sigma), as indicated,
was then added as final concentrations of 240 nM, 120 nM, and 24 nM respectively.
Digestion was carried out for 30 min and was stopped by the addition of an equal volume of
SDS loading buffer. Samples were denatured at 95 °C for 5 min. before analysis by 15 %
SDS-PAGE.
2.9 Thermal Inactivation of hGALT
Thermal inactivation of hGALT variants was judged kinetically using the forward reaction
setup described in section 2.8. Aliquots (100 μl) of each active variant hGALT at 0.5 μM
were incubated in 10 mM HEPES, pH 8.8 for 15 min at temperatures ranging from 30 to 70
°C (5 °C increments). These aliquots were chilled in ice immediately after incubation and
the residual activity was determined at 0.5 mM UDP-glucose and 1.0 mM galactose-1-
phosphate with 50 nM hGALT. Measurements were carried on three independent assays for
each temperature and the average activity was calculated with standard deviations. These
were normalized to the activity of each variant at 30 °C.
2.10 Differential scanning fluorimetry assay
Differential scanning fluorimetry was carried out essentially as previously described [39;40].
Protein samples were diluted in 10 mM HEPES, pH 8.8 to a final concentration of 5 μM and
any ligands used were added at a final concentration of 1 mM. Sypro orange (Sigma, Poole,
UK) was diluted from a 5000μ solution (manufacturer’s concentration definition) into a 50μ
solution with 10 mM HEPES, pH 8.8 and was mixed well prior to each use before 1 μl was
added to each mixture. Reactions were set up in a total volume of 20 μl in 0.2 ml PCR tubes
and controls of no protein added were always included.
Reaction mixtures were loaded into a Rotor-Gene Q cycler (Qiagen) and the following
protocol was used: High resolution melt run (460 nm source, 510 nm detector), 25 °C to 95
°C ramp with a 1 °C rise for each step and no gain optimisation. The melting temperatures,
(Tm), were calculated using the inbuilt analysis software. The shift in stability corresponding
to the change of melting temperature, ΔTm, for each variant and ligand binding were
calculated using equations (4) and (5) respectively.
(4)
(5)
To determine the significance of the differences in Tm the one way ANOVA with Dunnett
comparison test was used.
2.11 In silico analysis of variants
The homology model of hGALT, PDB 1R3A [41] was used to determine the location of
altered residues. Additional homology models of p.D28Y, p.L74P, p.F171S, p.F194L and
p.R333G hGALT, based on 1R3A, were obtained from the hGALT mutant structure
database [28] (http://bioinformatica.isa.cnr.it/GALT/). Structures were viewed using PyMol
(http://www.pymol.org/).
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Sequence alignment was carried out using ClustalW2 [42] and all sequences were obtained
from the UniProt database (http://www.uniprot.org/). Conserved residues, and those
involved in cofactor and metal binding were identified with ClustalW2.
In determining the effects on stability of hGALT mutants the following programs were used:
Dmutant [43], PoPMusic 2.1 [44], Cupsat [45], SDM [46], Eris [47], Concoord/PBSA [48],
I-Mutant 2.0 [49], MuPro [50], and Mustab [51]. When appropriate, the structure 1R3A was
used. Both thermal and denaturation options were used of the Cupsat server. Additionally
both flexible and inflexible backbone options were used of the Eris server. When using the
SDM server the mutant structures obtained from the hGALT mutant structure database were
used. The overall consensus of stability change was determined with the percentage of
agreeing predictions. All predictions were determined from the A chain contained in the
coordinate files.
Prediction of intrinsically disordered regions in hGALT was carried out using metaPrDOS
[52] and Spine-D [53]; metaPrDOS uses a consensus based approach using multiple
predictors. Both predict the probability of disorder and those residues with a probability of
0.5 and higher are deemed disordered. The regions predicted from these two servers were
mapped onto the homology model (1R3A) using PyMol.
The FTMap server [54] was used to predict any allosteric sites in hGALT. This server
predicts potential binding sites of proteins, which can act as the starting pointing of
identifying ’druggable hotspots’. In addition, this server can predict potential substrate
binding and allosteric sites [55]. FTMap uses a fragment-based approach that uses sixteen
small organic molecules to map these potential binding sites. This is based on a
crystallographic approach (Multiple Solvent Crystal Structures or MSCS) where structures
are solved in a number of different solvents containing organic solvents [54]. In addition to
FTMap, both Q-SiteFinder and Pocket-Finder [56] were used to predict potential binding
pockets. The homology structure 1R3A was submitted to these servers and the resulting sites
were visualised using PyMol.
3. Results
3.1 In silico analysis suggests alteration of overall protein charge, surface hydrophobicity
and monomer stability due to each amino acid substitution
Previously, a computational approach was used to understand how 107 missense mutations
cause their effects on hGALT structure and this suggested changes in residue interactions,
surface area and stability [28;29]. Here we extended this work by using a number of
different protein analysis servers to predict how p.D28Y, p.L74P, p.F171S, p.F194L and
p.R333G affect hGALT structure and function. This was done to improve the confidence of
our predictions since each of the algorithms has different strengths and weaknesses [57].
Initial analysis using PolyPhen-2 [58] and SIFT [59] suggested that all the mutations were
“probably damaging” and “damaging” respectively. In contrast only p.D28Y and p.R333G
were predicted to have altered overall charges and pI values of the linear protein chain as
predicted using the Protein Calculator version 3.3 (www.scripps.edu/~cdputnam/
protcalc.html). However, using the POPS server [60] and the hGALT mutant dimer
structures [28] all were predicted to have increases in surface hydrophobicity (Table S3A).
Further analysis using a number of different protein stability prediction servers suggested
that each mutation results in stability changes of hGALT monomer. Interestingly, the overall
consensus predicted both p.D28Y and p.F194L to be stabilised whereas p.L74P, p.F171S
and p.R333G were predicted to be destabilised (Table S3B). Previous studies using only two
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servers suggested that all are destabilised except p.D28Y where no definite prediction could
be made [28].
Taken together these analyses suggest that these residues are important in maintaining the
overall structure of hGALT. Furthermore protein sequence alignment revealed L74, F171
and R333 were strictly conserved across species, whereas D28 and F194 were not. However,
it was revealed that a hydrophilic residue (e.g. aspartate, glutamate or serine) is always at
position 28 and that F194 is conserved in all except yeast, where it is a serine (Figure S1).
3.2 Impact of disease-associated substitutions on hGALT activity measured in soluble
yeast lysates
As a first assessment of the functional consequence of each of the patient GALT alleles
described here, we expressed each in the context of a haploid strain of Saccharomyces
cerevisiae (baker’s yeast), JFy5555, which is deficient in the entire endogenous Leloir
pathway, and monitored GALT activity measured in vitro in soluble cell lysates. Budding
yeast represents a good, eukaryotic model for inherited metabolic diseases due to the
organism’s short generation time and the ease with which it can be genetically modified
[61-64]. However, it cannot recapitulate multicellular or tissue level consequences. Here, we
used it to understand how the disease-associated mutations affect GALT activity in a cellular
context. Two of the patient alleles tested, L74P and F171S, each demonstrated no detectable
activity above background (Table 1). For L74P this was a new finding; for F171S this result
had been observed previously as part of another study [19]. One allele, R333G,
demonstrated detectable, albeit residual (<1%), GALT activity above background, and
finally two alleles, D28Y and F194L, each demonstrated >10% wild-type activity (Table 1).
3.3 Effect of each substitution on the ability of hGALT to rescue galactose stressed yeast
As a test of function in vivo each patient allele was expressed in the haploid yeast strain
JFy3747 [21] which is missing endogenous GALT but expresses endogenous galactokinase
(Gal1p) and UDP-galactose 4′-epimerase/galactose mutarotase (Gal10p). JFy3747
expressing each hGALT allele were inoculated into medium containing 2% glycerol and 2%
ethanol in the presence vs. absence of 0.01% galactose. In the absence of galactose all of the
cultures grew well (data not shown), but in the presence of 0.01% galactose clear
distinctions were evident. As expected from prior studies [16;20;21] yeast expressing wild-
type hGALT grew well, and yeast expressing empty plasmid with no hGALT, completely
failed to grow (Figure 2). Also as expected, yeast expressing each of the two hGALT alleles
(D28Y and F194L) that demonstrated >10% residual GALT activity in vitro demonstrated
intermediate growth in the presence of 0.01% galactose (Figure 2). What was surprising,
however, was that the allele that demonstrated only marginal residual activity in vitro,
R333G, supported growth in the presence of galactose that was more robust than that seen
with either D28Y or F194L. The explanation for this apparent disparity in yeast between in
vitro and in vivo function for R333G-hGALT remains unclear but underscores the
complexity of the relationship between mutation, expression, and function in different
contexts.
3.5 Expression and purification of wild-type and mutant hGALT variants
The His-tagged wild-type and five mutant proteins were expressed and purified using a
modified E. coli expression system along with affinity and size exclusion chromatography.
Initial attempts at expression using a previous protocol [26;27] resulted in small amounts of
poor quality purified protein, which were not amenable to study. Using the E. coli Rosetta
strain coupled with decreasing the induction temperature to 15 °C and supplementing the
growth media with ZnCl2 increased the amount of expressed protein as judged by SDS-
PAGE (data not shown). During initial purification attempts precipitation also occurred
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frequently during dialysis, especially when the media or buffers were supplemented with
iron (II) ions. However, decreasing the pre-induction temperature from 37 °C to 30 °C
prevented precipitation with ZnCl2-supplemented media, but not those with FeCl2. This is
likely to be due to oxidation of Fe2+ to Fe3+. In the E. coli enzyme it has been shown that
Zn2+ is essential for maintenance of the structure and that Zn2+ can substitute for Fe2+ at a
second divalent cation binding site [65]. In addition, only Zn2+ has been confirmed to be
present in hGALT [24]. For these reasons iron supplementation was discontinued.
Furthermore size-exclusion chromatography was used instead of dialysis to decrease the
purification time; this allowed the oligomerisation state of each hGALT variant to be judged
(Figure 3A, B, C). This protocol resulted in roughly 1.0 mg of highly purified hGALT per
litre of initial bacterial culture (Figure 3D).
All hGALT variants were purified as dimers as judged by size-exclusion chromatography
(Figure 3C) and each was expressed and purified successfully using the modified protocol
(Figure 3D). Notably both F171S and F194L demonstrated some lower molecular weight
contaminants, which were likely to be degradation products.
3.6 Kinetic analysis of the forward and reverse reactions on the recombinant hGALT
variants reveals perturbed kinetic constants
Kinetic analysis of both the forward (UDP-Glc + Gal-1P → UDP-Gal + Glc-1P) and reverse
reactions (UDP-Gal + Glc-1P → UDP-Glc + Gal-1P) was carried out on all hGALT
variants. The wild-type protein demonstrated kinetics that fitted to three different kinetic
models and this depended on the variable substrate (Figure 4, Tables 3, 4). In the forward
reaction, varying UDP-Glc resulted in Michaelis-Menten kinetics with substrate inhibition,
whereas varying Gal-1P caused the enzyme to demonstrate classical Michaelis-Menten
kinetics. Kinetic analyses of the reverse reaction revealed that varying UDP-Gal resulted in
sigmoidal kinetics and that varying Glc-1P fitted best to Michaelis-Menten kinetics with
substrate inhibition. However, the kinetic parameters determined for the wild-type protein
are well within the range of values reported in the literature [23;26;27;37] and substrate
inhibition from both UDP-Glc and Glc-1P has been reported previously [19;66].
Interestingly hGALT demonstrated positive cooperativity in the reverse reaction with varied
UDP-Gal (Hill coefficient of 2.9 ± 0.3) and although there have been no definitive reports of
cooperativity for wild-type hGALT, there have been suggestions of this in purified
heterodimers of hGALT [12;67]. Submission of the wild-type homology model structure to
three binding site predictors [54;56], resulted in the prediction of an allosteric site at the
dimer interface on the opposite side of the enzyme to the active sites (Figure S2).
The variant hGALT proteins demonstrated altered kinetics with two, p.L74P and p.F171S,
showing no detectable activity in both the forward and reverse assays in the protein
concentration range studied (0 to 0.5 μM). This is in agreement with the yeast lysate
activities (Table 1) along with previous reports that these variants are inactive [19;20;31].
All other variants showed decreased activity with altered kinetic parameters and decreased
Hill coefficients (Tables 3, 4). p.D28Y (Figure S3) had the least altered kcat with only
slightly lower activity than the wild-type protein. Previously the specificity constants have
been used as an estimate of the rates of the formation and decay of the uridyl intermediate
[23]. Thus, p.D28Y was impaired in terms of uridylylation, for both reactions, as judged
from the specificity constants (Tables 3,4). This variant was more prone to substrate
inhibition from UDP-Glc with a Ki value nine times lower than that of the wild-type.
p.F194L (Figure S4) and p.R333G (Figure S5), however, did not show substrate inhibition
by UDP-Glc and had much lower activity than the wild-type and p.D28Y. For both p.F194L
and p.R333G, when UDP-Gal was varied, non-Michaelis-Menten kinetics were observed,
with large increases in activity at 700 μM UDP-Gal. This might be due to these proteins’
stabilities during storage; however, in the lower substrate range both fitted well to the
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Michaelis-Menten equation. These variants’ specificity constants revealed different levels of
impairment in uridylylation and deuridylylation for both reactions and each had altered
apparent Km and K0.5 values for all substrates (Tables 3,4).
3.7 Chemical cross-linking reveals that substrate binding alters the dimer interface
GALT only functions as a dimer and both active sites in the holoenzyme include residues
from both polypeptide chains [10;68;69]; it has been shown that specific mutations can
affect dimer formation [12;22;67]. Chemical cross-linking has been a useful tool in
determining whether other mutant proteins, involved in disease, have the potential to
oligomerise correctly [70]. Here we employed the cross-linkers BS3 and glutaraldehyde to
investigate the effects of ligands and point mutations. Both cross-linkers confirmed that all
hGALT variants form dimers (Figure 5A; S6A) in agreement with the size-exclusion
chromatography experiments (Figure 3C). Trimers were also detected with BS3 and other
higher molecular weight aggregates were detected when glutaraldehyde was used. These
may be artefactual due to the high ratio of cross-linker:protein.
Differences in cross-linking were detected in the presence of each UDP-sugar, sugar-
phosphate and appropriate UDP-sugar/sugar-phosphate pair from the forward and reverse
reactions. A pattern of slightly decreased and slightly increased cross-linking was detected
in the presence of a UDP-sugar and sugar-phosphate respectively (Figure 6B; S6B).
Addition of each UDP-sugar/sugar phosphate pair resulted in similar levels of cross-linking
to protein without substrate. Each hGALT variant showed similar responses to substrates
with cross-linkers to the wild-type protein, except for the enzymatically inactive p.L74P and
p.F171S. Although these variants could be cross-linked, little change in the crosslinking
pattern was seen in the presence of ligands (Figure 5B; S6B). This pattern was similar for
both cross-linkers suggesting these effects on dimerisation are due to protein-substrate
interactions and not an effect due to the cross-linker itself.
3.8 hGALT mutant proteins show differences in susceptibility to proteases which is altered
in presence of each substrate
Increased susceptibility to proteases can occur as a consequence of structural changes due to
mutation [71]. Carrying out limited proteolysis using thermolysin and trypsin revealed that
p.L74P, p.F171S and p.F194L have increased susceptibility to proteolytic degradation.
p.R333G showed little change in degradation. In contrast, p.D28Y was more resistant to
degradation (Figure 6A; S7A). Digestion with chymotrypsin gave less clear results, but
showed that p.D28Y hGALT is slightly more resistant to degradation whereas p.L74P
hGALT is slightly more susceptible (Figure S8A).
Since cross-linking was affected by the presence of each substrate, limited proteolysis was
carried out under similar conditions for all variants. Changes in protease susceptibility in the
presence of each substrate were detected and this followed a similar pattern to that observed
in the cross-linking experiments. Increased degradation was detected in the presence of both
sugar-phosphates, whereas a slight decrease in degradation occurred with both UDP-sugars.
Each UDP-sugar/sugar-phosphate pair showed similar levels of degradation to protease
treated protein with sugar-phosphate. This pattern occurred for all hGALT variants except
for p.L74P and p.F171S, where the presence of substrate(s) conferred little, or no, change in
degradation (Figure 6B; S7B). Additionally, p.F194L demonstrated no increase in
degradation in the presence of both UDP-sugar/sugar-phosphate pair. Again the same results
were obtained for both thermolysin and trypsin, but chymotrypsin resulted in less clear
results for p.F194L and p.R333G (Figure S8B). The common patterns resulting from
digestion with each protease suggest that these effects on degradation are due to protein-
substrate interactions and not an effect on the proteases.
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These findings of altered protease stability are in agreement with the suggestion from in
silico analysis that altered protein folding has occurred, but they do not agree with the
overall consensus for each variant. In addition, the decreased effect on stability from
substrates for p.L74P and p.F171S demonstrates that these variants have altered substrate
interactions, agreeing with the cross-linking and kinetic experiments.
3.9 hGALT mutants demonstrate altered intrinsic fluorescence and show an increased
surface hydrophobicity
hGALT contains 24 tryptophan residues per dimer and their excitation resulted in a broad
emission spectrum for the wild-type protein (Figure S9A). In comparison, all variants
studied, except p.D28Y, had increased relative emission intensity suggesting changes in the
microenvironment of the tryptophans most likely slight reorientation of one or more of these
residues towards a more hydrophobic environment or away from polar quenching groups
(Figure S9A).
In addition, as in silico analysis suggested changes in surface hydrophobicity, the binding of
the hydrophobic fluorescent probe ANS-1 to each variant was used to investigate any
misfolding in the ground state. All variants except p.D28Y had an increased ANS-1
fluorescence compared to the wild-type protein suggesting p.L74P, p.F171S, p.F194L and
p.R333G hGALT all have larger accessible hydrophobic surface areas (Figure 7A; S9B).
These fluorescence results suggest all variants tested, except p.D28Y hGALT, have an
altered conformation compared to the wild-type.
3.10 hGALT mutants show altered resistance to thermal denaturation
Thermal stability was first determined through thermal inactivation of enzyme activity.
Wild-type hGALT lost activity around 65 °C and p.D28Y was only slightly more resistant to
thermal denaturation. p.F194L and p.R333G, however, each lost activity at a much lower
temperatures than the wild-type (50 °C and 55 °C respectively) with p.R333G showing an
inactivation profile with increasing activity up to 45 °C (Figure 7B).
Since thermal inactivation was only applicable to those mutants that have activity,
differential scanning fluorimetry was carried out on all hGALT variants. This method uses
an extrinsic hydrophobic fluorophore (Sypro orange) to detect unfolding in the presence of
increasing temperature [72]. The melting temperature, Tm, is then calculated as the midpoint
between the maximum and initial minimum fluorescence allowing for comparison of
stability between variants. There is good agreement between DSF and differential scanning
calorimetry [72]. We have previously used this technique to study the stability changes in
human UDP-galactose 4′-epimerase due to ligand binding and disease-associated mutations
[39;40].
Figure 7C shows the unfolding curves of all six hGALT variants and Tm values are
presented in table S4. p.F171S was found to have a relatively high initial fluorescence signal
at 30 °C as did p.L74P and p.F194L, to lesser extents. This agrees with the respective
ANS-1 fluorescence results; however, p.R333G showed little difference in initial
fluorescence from the wild-type protein and this may be due to differences in the binding of
ANS-1 and Sypro orange or the starting temperature of this assay.
Thermal denaturation revealed that each hGALT variant had different Tm values and
unfolding profiles with the wild-type having a Tm of 63 °C. p.F194L and p.R333G were less
resistant to denaturation with lower Tm values of 48 °C and 56 °C respectively. In contrast,
p.D28Y was slightly more resistant with a Tm of 66 °C. p.L74P and p.F171S were also both
more resistant to denaturation with Tm values of 69 °C and 70 °C respectively. These
findings correlate well with the thermal inactivation results. Taken together these results
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demonstrate that each substitution causes alterations to the thermal stability of the hGALT
protein and that some show misfolding in the ground state.
3.11 Variant hGALT proteins show altered substrate binding
In addition to determining stabilities of proteins, DSF can also provide information about
substrate binding. Here the presence of a substrate can induce conformational changes which
can be inferred from the change in Tm (ΔTm) [73]. Tables 5 and S4 present the ΔTm and Tm
values of each hGALT variant in the presence of various substrates. Figure 7D shows the
unfolding curves of WT hGALT in the presence of UDP-Glc and Gal-1P. Wild-type and
p.D28Y hGALT showed similar, statistically significant increases in stability in the presence
of all substrates. Here both Glc-1P and Gal-1P resulted in similar ΔTm values of
approximately 6.5 K whereas UDP-Glc and UDP-Gal resulted in ΔTm values of
approximately 2.5 K. Both substrate pairs resulted in similar increases of stability of 6.5 K.
p.L74P and p.F171S differed, showing no significant changes in stability with each substrate
individually, although p.L74P appeared to be slightly destabilised in the presence of both
substrate pairs (ΔTm of −1.5 K). p.F194L also showed increases in stability for all
substrates, but not to the same extent as the wild-type protein. This variant showed
decreased stability with both sugar phosphates (ΔTm of 1.9 K), UDP-Gal (ΔTm of 0.5 K)
and both substrate pairs (ΔTm of 2.2 K). Interestingly, p.R333G showed the most different
behaviour when compared to the wild-type protein. The presence of UDP-Gal and Gal-1P
resulted in no significant changes, whereas UDP-Glc resulted in an increase of 1.6 K and
Glc-1P caused a decrease of −2.0 K. Additionally changes in stability in the presence of
each substrate pair appeared to be the sum of the results of each substrate on its own.
Overall these results indicate that the D28Y substitution does not cause any significant
changes in substrate binding, whereas both L74P and F171S appear to cause a substantially
decreased ability to bind substrates. p.F194L and p.R333G hGALT still have the ability to
bind substrates but not to the same extent as the wild-type protein.
4. Discussion
4.1 Structural bioinformatics analyses reveal further details of the effects of each
substitution on hGALT structure and function
A previous study used a homology model of hGALT to study the structural effects of 107
disease-associated variants of hGALT (http://bioinformatica.isa.cnr.it/GALT/) [29]. The
structures of the p.D28Y, p.L74P, p.F171S, p.F194L and p.R333G mutant proteins were
included in this study and their predicted structures allow for a more indepth analysis of how
these mutations cause their effects.
Asp-28 is located towards the N-terminus and near the dimer interface but is not part of the
active site. This residue forms a salt bridge with Arg-25 (Figure 8A) and its alteration to
tyrosine is predicted to have no direct effects on substrate interaction. However, Asp-28 also
forms a salt bridge with His-47 and this residue is in the same loop as Arg-48 and Arg-51
that are predicted to form contacts with the sugar and phosphate moieties of the opposite
subunit’s active site [29;69]. Mutating Asp-28 to tyrosine removes these salt bridges (Figure
8B). It has been shown that this loop containing equivalent residues in E. coli GALT shows
different conformations in the different crystal structures, being partially disordered, and this
is possibly due to interactions between it and the substrate [19;29]. It has been suggested
that this loop is involved in excluding water from the active site preventing the hydrolysis of
the uridyl-enzyme and participating in its energetically unfavourable formation [65].
Our studies on the wild-type protein suggest that conformational changes are important in
substrate binding, most likely in these active site loops (Figure 5B, 6B, S6B, S7B, S8B,
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Table 4). These loops in p.D28Y are likely to be less flexible due to the removal of a
connection to the highly flexible N-terminus as determined from predicted regions of
disorder of WT hGALT (Figure S10). This increases the enzyme’s overall stability (Figure
5A, S7A, S8A, 7C), but causes little change in the overall global conformation of the protein
(Figure 7A, S9). The decreased flexibility reduces the likelihood of the release of UDP-Glc
and Glc-1P thus increasing the apparent inhibition from these substrates (Table 2,3),
explaining the kinetic impairment. This is not the first report of an hGALT variant showing
increased inhibition and stability: a patient’s hGALT was more prone to substrate inhibition
by Glc-1P and was more thermally stable than the wild-type protein [74]. The specific
mutations involved were not identified but it is likely that they affected these active site
loops. In addition, since p.D28Y appears to affect the other subunit’s active site it can be
predicted that this mutation may be dominant negative and this further supports the
hypothesis that there is communication between the active sites.
Leu-74 is located at the dimer interface and active site of hGALT (Figure 8C). This
residue’s carbonyl oxygen hydrogen bonds with the side chains of both Cys-130 and Tyr-89,
whereas the backbone nitrogen hydrogen bonds to the side chain of Asn-72. The residue is
predicted to be located close to the uracil moiety and it has been suggested that mutating this
residue to proline removes van der Waal’s contacts between the residue and this part of the
substrate [10]. Mutating this leucine to proline only appears to remove the hydrogen bond
with Asn-72 on the same polypeptide chain (Figure 8D), as proline’s backbone nitrogen
cannot hydrogen bond. Leu-74 is flanked by a conserved cysteine and proline [31] and the
introduction of an additional proline would reduce the flexibility of this section of the
protein (Figure S10B) resulting in a more rigid structure. Additionally this variant is also
predicted to affect the flexibility of Asn-97 (Figure S10B), a residue that makes multiple
contacts with the nucleotide moiety of UDP-Gal (Figure 8D). This interpretation agrees well
with our in vitro findings that demonstrate that this variant is misfolded (Figure 6, 7A, S7A,
S8A, S9), yet thermally stabilised (Figure 7C, Table S4). Therefore this substitution is likely
to cause a conformational change at the active site resulting in improper binding of both
sugar-1-phosphates and UDP-sugars (Figure 5B, 6B, S6B, S7B, S8B, Table 4).
Phe-171 is also located at the dimer interface and active site as judged from the homology
model of hGALT (Figure 8E). This residue forms a hydrogen bond with Gln-188 of the
same subunit and its phenyl side chain is close to both Asn-172 and Tyr-339 of the other
polypeptide chain. Asn-172 forms hydrogen bonds to the phosphate moiety of the substrate
and Gln-188 is predicted to favour the nucleophilic attack of sugar 1-phosphates on the
uridylated enzyme and also stabilises the uridylated intermediate [27;75]. Previous studies
have predicted that this mutation displaces Gln-188 and forms new bonds between it and the
hydroxyl of Ser-171 [19]. In contrast, more recent modelling predicted that this hydrogen
bond forms between the serine hydroxyl and the carbonyl oxygen of the backbone of
Met-298 [29] (Figure 8F). This repositioning would have severe effects on activity as has
been previously determined for this mutant protein [19;20]. In addition, this substitution
replaces a hydrophobic residue with a polar residue, which may contribute to more general
misfolding.
It has been suggested that this mutation affects the secondary structure of this region of the
protein, since serine does not favour the formation of β-sheets [19]. Consistent with this,
F171S is predicted to increase the disorder of this region (Figure S10B) and is thus likely to
contribute to misfolding of the protein. In this study p.F171S showed similar effects on
enzyme function to p.L74P, as expected considering their similar location in the enzyme
(Figure 5, 6, S6, S7, S8, S9; Table 4). p.F171S is likely to cause similar conformational
changes in the active site and result in a protein which is misfolded as suggested from its
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higher surface hydrophobicity (Figure 7A, C). This variant was suggested to be incapable of
substrate binding [19] and our results are in agreement with this prediction.
Phe-194 is at the dimer interface and not at the active site (Figure 8G). The backbone of this
phenylalanine forms a hydrogen bond with Ser-192 of the same monomer. Importantly, the
side chain of Phe-194 is buried in a largely hydrophobic cleft containing residues from both
polypeptide chains: Leu-102a, Ala-122a, Ser-192a, Pro-196a, Ile-32b, Leu-43b and
Tyr-339b (where a and b represent residues from the two subunits). Substitution to leucine at
this position alters these hydrophobic interactions as its side chain points away from this
cleft resulting in increased solvent accessibility (Figure 8H). This is also predicted to cause a
slight decrease in the flexibility of the active site residue His-186 (Figure S10B). These
structural predictions agree well with our in vitro findings, which showed a higher surface
hydrophobicity (Figure 7A, C) and decreased thermal stability (Figure 7B, C). Therefore this
region of the protein must be important in stability and this mutation is likely to cause
conformational changes as suggested from this variant’s increased intrinsic fluorescence
(Figure S9) and decreased resistance to proteolysis (Figure 6, S7, S8). Unlike the active site
loops this section of the protein is highly ordered forming the scaffold for the active site
[29]. Misfolding of this section is likely to cause a conformational change at the active site,
altering substrate binding (Figure 5B, 6B, S6B, S7B, S8B, Table 4) and decreasing activity
(Table 2,3).
Arg-333 is at the dimer interface between the two active sites of the enzyme (Figure 8I).
This residue faces Arg-333 of the other monomer and appears not to be involved in any
interactions. Alteration of this residue to the smaller glycine results in a large void in the
middle of the hGALT dimer (Figure 8J) although not directly affecting any residues in the
active site. However, adjacent to this residue is Lys-334, which is predicted to form
hydrogen bonds to the hydroxyl groups of the sugar moiety of each substrate. Interestingly
the E. coli structure demonstrates slight conformational changes depending on the position
of the 4′-hydroxyl group of the substrate’s sugar moiety. This change is predominantly at
Glu-317 of the bacterial enzyme and suggests that the corresponding residue in the hGALT,
Glu-340, interacts with Lys-334 (Lys-311 in bacterial GALT) only when hGALT is UDP-
Gal bound. This lysine also interacts with 3′- and 4′-hydroxyl groups of both UDP-sugars
[69]. Arginine side chains are large and Arg-333 possibly reduces the flexibility of this
region due to the requirement to avoid steric clashes with the equivalent arginine of the other
subunit. Changing either residue to glycine decreases this residue’s size and possibly alters
that subunit’s flexibility at that location. Predictions, however, suggested that this alteration
slightly decreases the flexibility of this region (Figure S10B). This alteration of the
flexibility, and the void created, may explain this mutant’s decreased thermal stability
(Figure 7; Table S4), its increased surface hydrophobicity (Figure 8A) and its altered
intrinsic fluorescence (Figure S9A). Altered flexibility may also cause Lys-334 to change its
interaction with Glu-340 and the substrates thus interfering with the conformational change
when the enzyme binds a substrate. This may explain p.R333G’s severely impaired activity
in vitro (Table 2,3) and the effects on substrate binding (Figure 5B, 6B, S6B, S7B, S8B,
Table 4). The observation of non-Michaelis-Menten kinetics for both F194L and R333G
(Table 2,3) may also be due to their increased flexibilities.
4.2 The hGALT variants show characteristics of protein misfolding
As a large majority of disease-associated mutants of hGALT are not located at the active site
it has been suggested that they are likely to cause their affects by protein misfolding [15;29].
In this scenario alteration of the protein sequence reduces the amount of active protein by
conformational changes that perturb the active site, thus impairing substrate binding, the
formation and decay of the uridylated intermediate and altering the protein’s overall
stability. Taken together this study of five hGALT mutants has demonstrated that each
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causes unique changes of these aspects of the protein. All these effects are not mutually
exclusive and are caused by the removal of important interactions involved in the protein
structure and in substrate binding. From this it can be concluded that protein misfolding is
the underlying reason for these mutants’ enzymological impairment and adds compelling
evidence to this being a common molecular mechanism of hGALT deficiency in patients.
The contribution of uridyl-enzyme intermediate also needs to be considered. hGALT has
been shown to be present in vivo as a mixed population of uridylated and deuridylated
enzyme [25]. As such it is likely that the purified hGALT variants in this study are a mixed
population of these states. However, there is some uncertainty about the stability of the
intermediate as it has been shown kinetically that UMP can dissociate to reform the free
enzyme [27]. Interestingly if the uridylated enzyme is stable there are some hints of the
effects of uridylation in the data presented here. Both p.L74P and p.F171S are inactive
variants and probably do not form the covalent intermediate (similar to the inactive, artificial
variant p.H186G [25]). p.L74P and p.F171S showed a similar level of degradation by
proteases (Figure 6A, S7A) and melting temperatures (Table S4) as the wild-type in the
presence of a sugar 1-phosphate. The effects seen in this study on stability from sugar-1-
phosphates may be due to deuridylation and the effects of UDP-sugars could be due to dead-
end binding [19]. p.L74P and p.F171S may be misfolded and trapped in a deuridylated state.
Thus, those variants that are impaired in the formation of the intermediate may be more
prone to protease degradation. Further investigation of the contribution of the covalent
intermediate to enzyme stability is required.
4.3 Altered substrate binding: a consequence of protein misfolding
It has been shown that the ability to rescue galactose stressed null-GALT yeast correlates
with each variant’s activity [20]. This was observed for all variants in this study except for
p.R333G (Table S3B; Figure 2). However this is not the first time that a disparity of this
relationship has been found [20] and it is likely that some variants are more sensitive to
cellular environmental factors as also seen with UDP-galactose 4′-epimerase [35]. Activities
in yeast lysates also correlated well with those of the purified protein and it appears that
enzyme activity is roughly correlated with substrate binding and not overall stability as
determined by DSF. Inactive variants p.L74P and p.F171S show little change in thermal
stability whereas the least impaired variant, p.D28Y, shows similar changes to the wild-type
protein. p.F194L was the second most impaired active variant and showed clear, but lower,
stability changes than the wild-type protein. The least active variant, p.R333G, showed even
smaller changes in stability following substrate binding. This agrees with recent molecular
dynamic simulations that predicted that the wild-type protein demonstrates a conformational
change, becoming more compact when bound to UDP-Gal. Mutants were predicted to be
initially in a more compact structure before UDP-Gal binding and/or did not demonstrate a
conformational change after binding suggesting an alteration of substrate binding is the
cause of their impairment [30].
4.5 Conclusions
Since a common molecular mechanism of hGALT deficiency appears to be protein
misfolding it may be possible to develop “pharmacological chaperone” treatments. Here a
small ligand binds at the active site or novel binding pocket causing conformation changes
that increase the stability and activity of the protein. This treatment is already used in
phenylketonuria and has been suggested for other diseases [76-78]. Such small molecules
usually bind to cofactor or substrate binding sites and the latter may be appropriate for
hGALT. In addition, using the homology model 1R3A and three different binding site
predictors [54;56] (Figure S2), we have identified an additional binding pocket at the dimer
interface, on the opposite side of the active sites. The possible biological function of this
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predicted binding pocket is not known, but it may be involved in allosteric control of this
enzyme (Figure 4C). The detection of non-Michaelis-Menten kinetics suggests the potential
for allosteric activation or repression. This pocket could be targeted for pharmacological
chaperone treatment. In addition the use of proteostasis regulators may also beneficial,
decreasing the rate of degradation of unstable mutant proteins [79]. Such therapies for
galactosemia sufferers may alleviate the severity of the disease’s acute or long-term
pathology and/or allow for some relaxation of galactose restricted diets. Interestingly this
mechanism of a ligand-mediated increase in stability has been used to explain the findings
of increased hGALT activity in HepG2 cells in the presence of high concentrations of
galactose [80].
In summary we have measured the level of impairment of five hGALT variants in a yeast
model. Further research on the recombinant purified proteins demonstrated that these
hGALT variants are structurally altered, which affects thermal stability and protease
resistance. This, in turn, results in their decreased ability to bind substrates and lower
enzymatic activity. These new insights have revealed that the molecular basis of these
variants’ altered activity is due to protein misfolding and strongly suggests that this is a
common, underlying cause of hGALT deficiency in type I galactosemia. In view of these
findings we suggest that both pharmacological chaperone and proteostasis regulator
treatments should be investigated.
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BS3 suberic acid bis (3-sulfo-N-hydroxysuccinimide ester)
DSF differential scanning fluorimetry
GALT galactose-1-phosphate uridylyltransferase
Gal-1P galactose 1-phosphate
Glc-1P glucose 1-phosphate hGALT: human GALT
NAD+ oxidized nicotinamide adenine dinucleotide
NADH reduced nicotinamide adenine dinucleotide
NADP+ oxidized nicotinamide adenine dinucleotide phosphate
NADPH reduced nicotinamide adenine dinucleotide phosphate
DSF Differential scanning fluorimetry
UDP-Gal uridine diphosphate galactose
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• hGALT mutations demonstrate a range of activity changes in vivo and in vitro
• hGALT mutations alter both resistance against proteases and thermal stability
• Severely impairing mutations cause the greatest changes in substrate binding
• Protein misfolding is a fundamental, molecular cause of type I galactosemia
• Thus, pharmacological chaperones may prove to be a viable therapy
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Figure 1. Structure of hGALT and location of mutants analysed in relation to active site
The homology-modelled structure of the hGALT dimer is presented as a cartoon. Each
monomer is coloured light orange or light green. The residues altered by the disease-
associated mutations are highlighted in dark grey and presented in stick representations. The
active site residue, His-186 is also represented in a stick model and is highlighted in purple.
This figure was visualised in PyMol (www.pymol.org) using PDB entry 1R3A [41]. Readers
are directed to the online version of this article for the colour version of this figure.
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Figure 2. Yeast growth curves expressing each hGALT variant in the presence of 0.01%
galactose
Cultures of gal7-null yeast expressing either WT, no hGALT, p.D28Y-hGALT, p.L74P-
hGALT, F171S-hGALT, F194L-hGALT or R333G-hGALT were inoculated into 96-
wellplates in SGE-trp medium with the indicated amount of galactose added at t = 0. Growth
of each culture was monitored at OD600. Plotted values represent means ± SD; n = 3.
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Figure 3. Expression and purification of recombinant hGALT from E. coli using size exclusion
chromatography
(A) WT hGALT purification was resolved by SDS-PAGE (10%) and visualised by staining
with Coomassie blue. M = molecular mass markers (kDa). (B) Size exclusion
chromatography standard curve. The proteins used for standards are as follows A:
Ribonuclease (13.7 kDa); B: Chymotrypsinogen A (25 kDa); C: Ovalbumin (43 kDa); D:
Serum albumin (67 kDa) E: Alcohol dehydrogenase (149.5 kDa); F: Thyroglobulin (669
kDa). (C) Chromatograms of wild-type and mutant hGALT proteins. All the proteins eluted
mainly at the expected dimer molecular mass. However p.L74P, p.F171S and p.F194L
showed increases in the absorbance at approximately one column volume suggesting some
degradation to smaller peptides had occurred. (D) Purified hGALT variants resolved by
SDS-PAGE (10 %) and visualised by staining with Coomassie blue. M = molecular mass
markers (kDa). Readers are directed to the online version of this article for the colour
version of this figure.
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Figure 4. The steady state enzyme kinetics for WT hGALT in the forward and reverse reaction
(A) The steady state enzyme kinetics for WT hGALT in the forward reaction with varied
UDP-Glc and 1 mM Gal-1P. The kinetic data fitted best to the Michaelis-Menten equation
with substrate inhibition with the following constants: ,
,  μmol Glc-1P.min−1.mg−1. (B) The steady state
enzyme kinetics in the forward reaction with varied Gal-1P and 500 μM UDP-Glc. The
kinetic data fitted best to the Michaelis-Menten equation with the following constants:
,  μmol Glc-1P.min−1.mg−1. (C) The steady state
enzyme kinetics for WT hGALT in the reverse reaction with varied UDP-Gal and 1 mM
Glc-1P. The kinetic data fitted best to the Hill equation (sigmoidal kinetics) with the
following constants: ,  μmol UDP-Glc.min−1.mg−1, h
= 2.9. (D) The steady state enzyme kinetics in the reverse reaction with varied Glc-1P and
500 μM UDP-Gal. The kinetic data fitted best to the Michaelis-Menten equation with
substrate inhibition with the following constants: ,
,  μmol UDP-Glc.min−1.mg−1. WT hGALT
(10 nM) was used for both forward and reverse reactions and controls with no GALT always
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gave no activity. Each point represents the mean of three independent determinations of the
rate and the error bars represent the standard deviations of these means.
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Figure 5. Chemical cross-linking of hGALT variants with BS3 in comparison to the wild-type
hGALT and in the presence of various substrates
(A) The hGALT variants showed little difference in their ability to form dimers in
comparison to the wild-type. Higher order oligomers were also formed in the presence of
cross-linker. C: control, protein (5 μM) with no cross-linker; +: protein (5 μM) with the
cross-linker BS3 (100 μM). (B) Active and inactive hGALT variant show different substrate
dependent effects on dimerisation as determined by cross-linking. C: control, protein (5 μM)
with no cross-linker; +: protein (5 μM) with BS3 (100 μM) in the presence of various
substrates (1 mM). Gal-1P: galactose 1-phosphate; UDP-glc: uridine diphosphate glucose;
Glc-1P: glucose 1-phosphate; UDP-gal; uridine diphosphate galactose; For: galactose 1-
phosphate and uridine diphosphate glucose; Rev: glucose 1-phosphate and uridine
diphosphate galactose.
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Figure 6. Limited proteolysis of hGALT variants in comparison to the wild-type hGALT and in
the presence of various substrates
(A) The hGALT variants showed differences in susceptibly to degradation by the protease
thermolysin in comparison to the wild-type. C: control, protein (5 μM) with no protease; +:
protein (5 μM) with thermolysin (240 nM). (B) WT hGALT showed substrate dependent
effects on the susceptibility to proteolysis where sugar 1-phosphates increased degradation
and uridine diphosphate sugars had little effect. Additionally this increased degradation due
to sugar 1-phosphates is the most dominant affect when the protein was in the present of
both a sugar 1-phosphate and uridine diphosphate sugar. Active and inactive hGALT
variants show different substrate dependent effects on protease sensitivity. C: control,
protein (5 μM) with no protease; +: protein (5 μM) with thermolysin (240 mM) in the
presence of various substrates (1 mM). Gal-1P: galactose 1-phosphate; UDP-glc: uridine
diphosphate glucose; Glc-1P: glucose 1-phosphate; UDP-gal; uridine diphosphate galactose;
For: galactose 1-phosphate and uridine diphosphate glucose; Rev: glucose 1-phosphate and
uridine diphosphate galactose.
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Figure 7. Surface hydrophobicity and thermal stability of hGALT variants
(A) Relative surface hydrophobicity of each hGALT variant as judged by ANS-1 binding.
The emission (at 480 nm) of ANS-1 binding was measured following excitation at 370 nm.
The average fluorescence and standard deviation was calculated from three independent
assays with each corrected for ANS-1 alone. The significance of change in fluorescence in
comparison to the wild-type was determined using one-way ANOVA with a Dunnett’s post-
test. (B) Thermal inactivation of wild-type hGALT and active variants (p.D28Y, p.F194L
and p.R333G) at 50 nM. Aliquots (100 μl) of each variant hGALT (0.5 μM) were incubated
in HEPES (10 mM), pH 8.8 for 15 min at temperatures ranging from 30 to 70 °C. Residual
activity of the forward reaction was determined with 0.5 mM UDP-Glc and 1.0 mM Gal-1P.
Activities were normalized to those at 30 °C. Three independent assays for each temperature
were carried out and the points show the average activity and the error bars the standard
deviations of these means. (C) Each hGALT variant showed a unique melting curve and
susceptibility to thermal denaturation as judged by DSF. Melting temperatures, (Tm) are
presented in table S2. (D) Melting profiles and melting temperatures of WT hGALT with
and without Gal-1P or UDP-Glc. WT hGALT showed a shift in stability when Gal-1P or
UDP-Glc was present consistent with binding to the substrate and consequent stabilisation
of the substrate. Melting temperatures, (Tm) are presented in table S2. Reaction mixtures
contained 5 μM protein, 1 mM ligand and 2.5× Sypro orange (manufacturer’s concentration
definition) dissolved in 10 mM HEPES pH 8.8. Controls contained no protein. Assays were
set up in triplicate and the curves were constructed from the mean fluorescence values; the
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error bars represent the standard deviations of these means. Readers are directed to the
online version of this article for the colour version of this figure.
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Figure 8. Amino acids affected by hGALT mutations affect side-chain and substrate interactions
(A) Asp-28 is located in the N-terminal loop at the dimer interface and forms a number of
hydrogen bonds, one of which is with His-47. This residue is on the same loop as Arg-48
and Arg-51 that form part of subunit B’s active site. (B) p.D28Y results in the removal of
the interaction between this residue and His-47. (C) Leu-74 is located at the active site and
is flanked by Pro-73 and Cys-75. This residue forms hydrogen bonds with Cys-130 and
Tyr-89 via its backbone oxygen and with Asn-72 via the backbone nitrogen. (D) p.L74P
results in the removal of the hydrogen bond with Asn-72. Leu-74 is predicted to be close to
the uracil moiety of UDP-Glc and possibly interacts hydrophobically. (E) The residue
Phe-171 is located at the active site and the dimer interface. It is close to Gln-188 and forms
only backbone interactions with this residue. (F) p.F171S results in an additional hydrogen
bond between the side chain hydroxyl and backbone oxygen of Met-298. (G) Phe-194 is
located at the dimer interface and exterior of hGALT. This residue forms hydrogen bonds
between its backbone oxygen with the hydroxyl of Ser-192. The side chain of Phe-194 is
buried in a largely hydrophobic cleft containing residues from both polypeptide chains. (H)
p.F194L results in a smaller side chain that points more towards the exterior of the protein.
(I) Arg-333 is predicted to be part of a number of loops at the dimer interface between the
two active sites. This residue is facing the Arg-333 of the other subunit and beside Lys-334
that is predicted to interact with the sugar moiety of either substrate [29]. (J) Alteration of
arginine to glycine at residue 333 results in a void at the dimer interface due to the smaller
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size of the side chains. Subunit backbones are ribbon representations with subunit A in pale
green and subunit B in light orange. Selected residues are shown as stick models in white
with nitrogen, oxygen, phosphate and sulphur atoms in blue, red, orange and yellow
respectively. Residues affected by mutation are in dark grey and hydrogen bonds are shown
as black dotted lines. His-186 is shown in purple and the substrate UDP-Glc is shown in
cyan. Structures are from the hGALT structure [28]. Readers are directed to the online
version of this article for the colour version of this figure.
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Table 1
GALT activity levels observed in null-background yeast expressing each hGALT allele from a centromeric
plasmid.
hGALT variant nucleotide change % wild-type activity(mean ± SD) n=3
WT N.A. 100 ± 0.00
no GALT N.A. 0.01 ± 0.03
p.D28Y c.82G>T 13.55 ± 5.72
p.L74P c.221T>C 0.01 ± 0.09
p.F171S c.512T>C −0.03 ± 0.01
p.F194L c.580T>C 11.93 ± 2.00
p.R333G c.997C>G 0.60 ± 0.07
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